Blume Capital Management Inc. trimmed its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 42.0% during the 4th quarter, HoldingsChannel reports. The firm owned 29,638 shares of the financial services provider’s stock after selling 21,437 shares during the quarter. Blume Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $5,002,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the company. Odyssey Capital Advisors Inc. bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth about $479,000. TD Private Client Wealth LLC increased its holdings in shares of iShares Biotechnology ETF by 164.7% in the fourth quarter. TD Private Client Wealth LLC now owns 17,225 shares of the financial services provider’s stock worth $2,907,000 after purchasing an additional 10,717 shares during the last quarter. Leuthold Group LLC increased its holdings in shares of iShares Biotechnology ETF by 41.0% in the fourth quarter. Leuthold Group LLC now owns 18,188 shares of the financial services provider’s stock worth $3,070,000 after purchasing an additional 5,285 shares during the last quarter. Beese Fulmer Investment Management Inc. bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth about $228,000. Finally, Millennium Capital Advisors LLC bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth about $275,000. 62.45% of the stock is owned by institutional investors.
iShares Biotechnology ETF Price Performance
Shares of IBB stock opened at $166.83 on Monday. iShares Biotechnology ETF has a 12-month low of $118.51 and a 12-month high of $179.64. The stock’s 50-day moving average price is $169.24 and its 200-day moving average price is $169.66.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
